|Bid||106.54 x 1000|
|Ask||121.02 x 1100|
|Day's range||105.15 - 110.73|
|52-week range||78.44 - 131.73|
|Beta (5Y monthly)||1.09|
|PE ratio (TTM)||47.57|
|Earnings date||26 Jan 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||129.52|
Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Improvement in TAVR and TMTT businesses is expected to have contributed to Edwards Lifesciences' (EW) fourth-quarter results.
Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.